The World CML Day

CML results from a transformation of a stem cell caused in about 95% of Chronic Myeloid Leukemia patients by the change of chromosomes 9 and 22, which is why World CML Day (9/22) carries a symbolic significance for the patient community.

This day was initiated in 2008 by the patient community to bring awareness about patients’ needs to the general public, politicians and medical professionals across the world.

To face this challenge, every 22 September the entire Chronic Myeloid Leukemia community stands together to raise awareness about one life-changing reality – living with CML.

The CML Advocates Network annually coordinates the World CML Day global awareness campaign to support our 122 members worldwide.

Incyte donated € 20,000 at EHA 2019 Congress

During the 24th European Hematology Association Congress, Incyte developed an interactive initiative by launching a Quiz based on CML basic disease information. Hundreds of Congress delegates have played the game that was located at the company’s booth at the Exhibition Area of the Congress.

By playing this game whilst learning about CML, the EHA delegates accumulated points that converted to donations, Raising a total of €20,000 that was donated to the CML Advocates Network for World CML Day campaign.

At the end of the 2nd day of the EHA Congress, Mr. Jonathan Dickinson, Executive Vice President and General Manager, Europe, Incyte, presented the cheque to the CML Advocates Network.

On behalf of the global World CML Day campaign, we would like to say thank you and share our gratitude for this donation supporting the CML community.

We will continue raising the voice of the CML patients and tackling the many challenges that people still face such as access to quality therapies and diagnostics, treatment, adherence to therapy, effective side effect management and development of a cure that can only be tackled in partnership between patients, healthcare providers and researchers.

We will keep on raising the voice of the CML patients and facing the CML challenges such as access to high-quality therapies and diagnostics, treatment according to expert recommendations, adherence to therapy, effective side effect management and development of a cure that can only be tackled in partnership between patients, healthcare providers and researchers.